MedTrace Logo

Tannin Specific Natural Extract for COVID-19 Infection

NCT04403646 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2020-12-22

No results posted yet for this study

Summary

There is an urgent need to evaluate interventions that could be effective against the infection with SARS-CoV 2. Tannins based wood extracts are an inexpensive and safe product with protective effect in both bacterial and viral infections likely due to its anti- inflammatory, anti-oxidative effects and their modulation of the intestinal microbiota. This randomized controlled trial seeks to evaluate the efficacy of the tannins based dietary supplement ARBOX in positive COVID-19 patients.

Conditions

  • COVID-19
  • SARS-CoV 2
  • Coronavirus Infection

Interventions

DIETARY_SUPPLEMENT

ARBOX

dry extract of polyphenols (tannins) form quebracho and chestnut 240 mg, B12 vitamin 0.72 µg

OTHER

PLACEBO

Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for ARBOX

Sponsors & Collaborators

  • SILVATEAM

    collaborator UNKNOWN

  • Hospital de Clinicas José de San Martín

    lead OTHER

Principal Investigators

  • Maria M Piskorz, MD · Hospital de Clinicas Universidad de Buenos Aires

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-12
Primary Completion
2020-10-20
Completion
2020-11-01

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04403646 on ClinicalTrials.gov